Contact
searchSearch
HMP Global
Login

Multiple Myeloma Specialty Channel

Multiple Myeloma
Specialty Channel
Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
MRI Radiomics Show Accuracy in Predicting High-Risk Cytogenetic Abnormalities Among Patients With Multiple Myeloma
03/03/2025
Emily Estrada
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic...
03/03/2025
Oncology
News
Predictors of Outcomes and Efficacy of Isatuximab, Pomalidomide, and Dexamethasone Therapy for Patients With Daratumumab Refractory MM
03/03/2025
Emily Estrada
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key...
03/03/2025
Oncology
News
Second High-Dose Therapy and Autologous Stem Cell Transplant Demonstrates Efficacy and Tolerability for Patients With MM in First Relapse
03/03/2025
Emily Estrada
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously...
03/03/2025
Oncology
News
GPRC5D-Targeted CAR T-Cell Therapy Demonstrates Efficacy and Safety for Patients With R/R MM
02/24/2025
Emily Estrada
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting...
02/24/2025
Oncology
Mateo Mejia Saldarriaga, MD
Videos
Comparability of CAR-T Therapies for Patients With R/R Multiple Myeloma
02/12/2025
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD...
02/12/2025
Oncology
Melissa Alsina, MD
Conference Coverage
Quadruplet Therapy for Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
02/12/2025
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses...
02/12/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Superior Efficacy Compared With Idecabtagene Vicleucel for Treatment of Triple-Class-Exposed R/R MM
02/10/2025
Emily Estrada
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel...
02/10/2025
Oncology

News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
MRI Radiomics Show Accuracy in Predicting High-Risk Cytogenetic Abnormalities Among Patients With Multiple Myeloma
03/03/2025
Emily Estrada
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic...
03/03/2025
Oncology
News
Predictors of Outcomes and Efficacy of Isatuximab, Pomalidomide, and Dexamethasone Therapy for Patients With Daratumumab Refractory MM
03/03/2025
Emily Estrada
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key...
03/03/2025
Oncology
News
Second High-Dose Therapy and Autologous Stem Cell Transplant Demonstrates Efficacy and Tolerability for Patients With MM in First Relapse
03/03/2025
Emily Estrada
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously...
03/03/2025
Oncology
News
GPRC5D-Targeted CAR T-Cell Therapy Demonstrates Efficacy and Safety for Patients With R/R MM
02/24/2025
Emily Estrada
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting...
02/24/2025
Oncology
Mateo Mejia Saldarriaga, MD
Videos
Comparability of CAR-T Therapies for Patients With R/R Multiple Myeloma
02/12/2025
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD...
02/12/2025
Oncology
Melissa Alsina, MD
Conference Coverage
Quadruplet Therapy for Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
02/12/2025
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses...
02/12/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Superior Efficacy Compared With Idecabtagene Vicleucel for Treatment of Triple-Class-Exposed R/R MM
02/10/2025
Emily Estrada
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel...
02/10/2025
Oncology

Interactive Features

Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology
Quiz
Treating R/R Multiple Myeloma With Fractionated BCMA-Directed CAR T-Cell Therapy ARI0002h
01/30/2024
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis...
01/30/2024
Oncology
Quiz
Mezigdomide Plus Dexamethasone Oral Combination for Patients With Heavily Pretreated R/R MM
01/19/2024
True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.
True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.
True or False: The oral...
01/19/2024
Oncology
Quiz
Quiz: Ciltacabtagene Autoleucel CAR T-Cell Therapy for Patients With R/R Multiple Myeloma With Prior BCMA-Targeting Therapy
04/18/2023
In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...
In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...
In a study assessing the...
04/18/2023
Oncology
Quiz
Quiz: Triplet Therapy With Lenalidomide, Bortezomib, and Dexamethasone Alone or With Autologous SCT for MM
09/13/2022
True or False: Among adults with multiple myeloma, triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus autologous stem-cell transplantation was associated with longer progression-free survival than RVD alone, according...
True or False: Among adults with multiple myeloma, triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus autologous stem-cell transplantation was associated with longer progression-free survival than RVD alone, according...
True or False: Among adults with...
09/13/2022
Oncology
Quiz
Quiz: Responses to MRD-Adapted Study Design Employing Quadruplet Therapy Without Transplant in Patients With MM
09/02/2022
True or false: In a phase 2 study, an MRD-adapted study design employing a quadruplet therapy regimen of elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in...
True or false: In a phase 2 study, an MRD-adapted study design employing a quadruplet therapy regimen of elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in...
True or false: In a phase 2...
09/02/2022
Oncology
Quiz
Quiz: Treatment With Teclistamab for Patients With Triple-Class Exposed Relapsed/Refractory MM
08/24/2022
Quiz: Among patients with triple-class exposed relapsed/refractory MM on a phase 1-2 study, treatment with teclistamab led to an overall response rate of which of the following?
Quiz: Among patients with triple-class exposed relapsed/refractory MM on a phase 1-2 study, treatment with teclistamab led to an overall response rate of which of the following?
Quiz: Among patients with...
08/24/2022
Oncology
Test Your Knowledge
Quiz: Is TNB-383B Well Tolerated in R/R MM?
02/01/2022
True or false: TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, is not well tolerated in patients with R/R MM.
True or false: TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, is not well tolerated in patients with R/R MM.
True or false: TNB-383B, a BCMA...
02/01/2022
Oncology
Test Your Knowledge
Quiz: Do Gamma Secretase Inhibitors Increase BCMA Expression?
02/01/2022
True or false: Gamma secretase inhibitors increase BCMA expression on MM cells.
True or false: Gamma secretase inhibitors increase BCMA expression on MM cells.
True or false: Gamma secretase...
02/01/2022
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
MRI Radiomics Show Accuracy in Predicting High-Risk Cytogenetic Abnormalities Among Patients With Multiple Myeloma
03/03/2025
Emily Estrada
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic...
03/03/2025
Oncology
News
Predictors of Outcomes and Efficacy of Isatuximab, Pomalidomide, and Dexamethasone Therapy for Patients With Daratumumab Refractory MM
03/03/2025
Emily Estrada
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key...
03/03/2025
Oncology
News
Second High-Dose Therapy and Autologous Stem Cell Transplant Demonstrates Efficacy and Tolerability for Patients With MM in First Relapse
03/03/2025
Emily Estrada
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously...
03/03/2025
Oncology
News
GPRC5D-Targeted CAR T-Cell Therapy Demonstrates Efficacy and Safety for Patients With R/R MM
02/24/2025
Emily Estrada
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting...
02/24/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Superior Efficacy Compared With Idecabtagene Vicleucel for Treatment of Triple-Class-Exposed R/R MM
02/10/2025
Emily Estrada
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel...
02/10/2025
Oncology
News
Talquetamab Plus Teclistamab Combination Therapy Demonstrates Durable Responses, High Infection Incidence for Patients With R/R MM
02/07/2025
Emily Estrada
Talquetamab plus teclistamab therapy for relapsed/refractory multiple myeloma demonstrated durable responses among patients, however, risk for grade 3 or 4 infections were higher than either therapy alone, according to a recent study.
Talquetamab plus teclistamab therapy for relapsed/refractory multiple myeloma demonstrated durable responses among patients, however, risk for grade 3 or 4 infections were higher than either therapy alone, according to a recent study.
Talquetamab plus teclistamab...
02/07/2025
Oncology
News
Ciltacabtagene Autoleucel Effective, Feasible for Treatment of R/R Multiple Myeloma in Real-World Population Setting
01/15/2025
Emily Estrada
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use